U.S Healthcare Conferences Press Release - May 05, 2022
Sernova to Participate in Multiple U.S. Healthcare Investor Conferences
Sernova Engages Leading U.S.-Based Healthcare Communications Firm to Broaden Awareness of Potential ‘Functional Cure’ Technology for Type 1 Diabetes
LONDON, ONTARIO – May 5, 2022 – Sernova Corp. (TSX-V:SVA) (OTCQB:SEOVF) (FSE/XETRA:PSH), a clinical stage regenerative medicine company focused on developing a potential ‘functional cure’ for type 1 diabetes (T1D) and other chronic diseases including hemophilia A and thyroid disease, today announced that the company will be participating in several upcoming U.S. healthcare industry and investor conferences. Conference details are provided below.
The Company is also pleased to announce it has engaged New York-based LifeSci Communications, a global life science and medical technologies-focused communications and marketing agency. LifeSci Communications will assist Sernova to expand and elevate its profile through strategic communications and public relations. Sernova is also working with affiliate LifeSci Advisors LLC, a leading investor relations consultancy firm serving life science companies, providing institutional investor communications and capital markets outreach services in support of the Company’s U.S. capital markets objectives.
“With multiple collaborations advancing across our pipeline and growing interest in our best-in-class cell therapy therapeutic solution platform - consisting of immune protected therapeutic cells and our proprietary Cell Pouch™ medical device - as a potential ‘functional cure’ for multiple patient populations, the timing is right to drive awareness of our unique cell therapy proposition and unprecedented clinical results including the demonstration of continuous insulin independence for over two years now in our most advanced Phase 1/2 T1D study patient, in contrast to the clinical setbacks of several of our peer companies,” commented Dr. Philip Toleikis, President & CEO of Sernova.
UPCOMING U.S. HEALTHCARE INDUSTRY AND INSTITUTIONAL INVESTOR PRESENTATIONS
Event: Roth Capital’s Canada Corporate Access Day Date: May 17, 2022 Format: Corporate presentation and 1x1 meetings with institutional investors Location: New York, NY Event: H.C. Wainwright Global Life Sciences Conference Date: May 24-25, 2022 Format: Corporate presentation and 1x1 meetings with institutional investors Location: Miami Beach, FL Event: Truist Securities Cell Therapy Symposium Date: June 28, 2022 Format: Panel expert and discussions Location: New York, NY
ABOUT SERNOVA Sernova is developing regenerative medicine cell therapeutic solutions using a medical device (Cell Pouch) and immune protected therapeutic cells / tissues (i.e. human donor cells, corrected human cells and stem cell- derived cells) to improve the treatment and quality of life of people with chronic metabolic diseases such as insulin-dependent diabetes, blood disorders including hemophilia, and other diseases treated through cellular production of proteins or hormones missing or in short supply within the body.